what is better for weight loss semaglutide or tirzepatide vs Tirzepatide vs Semaglutide 2026: 22%

Abbreviations AACE/ACE: American Association of Clinical Endocrinologists/American College of Endocrinology ADA: American Diabetes Association ASCVD: Atherosclerotic cardiovascular disease AUC: Area under the curve C avg : Average plasma concentration CI: Confidence interval C max : Maximum concentration CV: Cardiovascular CVD: Cardiovascular disease CVOT: Cardiovascular outcomes trial DPP-4: Dipeptidyl peptidase-4 empa: empagliflozin ETD: Estimated treatment difference FDA: Food and Drug Administration GI: Gastrointestinal GLP-1: Glucagon-like peptide-1 GLP-1RA: Glucagon-like peptide-1 receptor agonist GRAS: Generally regarded as safe HbA 1c : Glycated hemoglobin HR: Hazard ratio imp.: impairment lira: liraglutide MACE: Major adverse cardiovascular events met: metformin OAD: Oral antidiabetes drug pbo: placebo s.c.: subcutaneous sema: semaglutide SGLT2i: Sodium-glucose co-transporter-2 inhibitor sita: sitagliptin SNAC: Sodium N-(8-[2-hydroxybenzoyl]amino)caprylate SU: Sulfonylurea t 1/2 : Terminal half-life T2D: Type 2 diabetes T max : Time to maximum concentration References Lau JL, Dunn MK

This mechanism reduces the risk of hypoglycemia when used alone, though this risk increases when tirzepatide is combined with insulin or sulfonylureas

Its great for stubborn areas that are resistant to diet and exercise like your abdomen, waist, thighs, and arms

Compounded Medication Considerations Because the Ivm Health GLP-1 ID program uses compounded formulations that have not undergone FDA review, patients should be aware that: The safety profile may differ from FDA-approved formulations Quality control processes vary by compounding pharmacy Concentration accuracy may have more variability than pre-filled pens Long-term safety data specific to compounded formulations is limited Patients should report any side effects to their healthcare provider through the weekly check-in system and seek immediate medical attention for severe symptoms such as persistent severe abdominal pain, signs of pancreatitis, or allergic reactions

FDA status and regulatory landscape The regulatory story behind tirzepatide ODT is complex, and understanding it is essential for anyone evaluating their current options

Wallner M, Kolesnik E, Ablasser K, et al